175 related articles for article (PubMed ID: 32476174)
1. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.
Wang H; Long-Boyle J; Winger BA; Nicolaides T; Mueller S; Prados M; Ivaturi V
J Clin Pharmacol; 2020 Sep; 60(9):1209-1219. PubMed ID: 32476174
[TBL] [Abstract][Full Text] [Related]
2. Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAF
Zhang W; Mathisen M; Goodman GR; Forbes H; Song Y; Bertran E; Demidov L; Shin SJ
Clin Pharmacol Drug Dev; 2021 Jan; 10(1):39-45. PubMed ID: 32602215
[TBL] [Abstract][Full Text] [Related]
3. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924
[TBL] [Abstract][Full Text] [Related]
4. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
5. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
6. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.
Grippo JF; Zhang W; Heinzmann D; Yang KH; Wong J; Joe AK; Munster P; Sarapa N; Daud A
Cancer Chemother Pharmacol; 2014 Jan; 73(1):103-11. PubMed ID: 24178368
[TBL] [Abstract][Full Text] [Related]
7. Response to combined BRAF/MEK inhibition in adult BRAF V600E mutant spinal pilocytic astrocytoma.
Balasubramanian A; Gunjur A; Gan HK; Perchyonok Y; Cher LM
J Clin Neurosci; 2020 Sep; 79():269-271. PubMed ID: 33070910
[TBL] [Abstract][Full Text] [Related]
8. Pilomyxoid astrocytoma treated successfully with vemurafenib.
Skrypek M; Foreman N; Guillaume D; Moertel C
Pediatr Blood Cancer; 2014 Nov; 61(11):2099-100. PubMed ID: 24821190
[TBL] [Abstract][Full Text] [Related]
9. Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF
Zhang W; McIntyre C; Riehl T; Forbes H; Bertran E; Choi HJ; Lee DH; Lee J
Clin Pharmacol Drug Dev; 2020 Jul; 9(5):651-658. PubMed ID: 32311241
[TBL] [Abstract][Full Text] [Related]
10. BRAF Inhibition in
Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
[TBL] [Abstract][Full Text] [Related]
11. Somatic BRAF c.1799T>A p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities.
Watanabe Y; Shido K; Niihori T; Niizuma H; Katata Y; Iizuka C; Oba D; Moriya K; Saito-Nanjo Y; Onuma M; Rikiishi T; Sasahara Y; Watanabe M; Aiba S; Saito R; Sonoda Y; Tominaga T; Aoki Y; Kure S
Am J Med Genet A; 2016 Jan; 170A(1):189-94. PubMed ID: 26360803
[TBL] [Abstract][Full Text] [Related]
12.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
13. Cutaneous adverse events in children treated with vemurafenib for refractory BRAF
Tardieu M; Néron A; Duvert-Lehembre S; Amine Larabi I; Barkaoui M; Emile JF; Seigneurin A; Boralevi F; Donadieu J
Pediatr Blood Cancer; 2021 Sep; 68(9):e29140. PubMed ID: 34109735
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.
Chamberlain MC
J Neurooncol; 2013 Sep; 114(2):237-40. PubMed ID: 23756728
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.
Kramkimel N; Thomas-Schoemann A; Sakji L; Golmard J; Noe G; Regnier-Rosencher E; Chapuis N; Maubec E; Vidal M; Avril M; Goldwasser F; Mortier L; Dupin N; Blanchet B
Target Oncol; 2016 Feb; 11(1):59-69. PubMed ID: 26208946
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
[TBL] [Abstract][Full Text] [Related]
18. Effect of Rifampicin on the Pharmacokinetics of a Single Dose of Vemurafenib in Patients With BRAF
Zhang W; McIntyre C; Forbes H; Gaafar R; Kohail H; Beck JT; Plestina S; Bertran E; Riehl T
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):837-843. PubMed ID: 30570831
[TBL] [Abstract][Full Text] [Related]
19. BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Chisholm JC; Suvada J; Dunkel IJ; Casanova M; Zhang W; Ritchie N; Choi Y; Park J; Das Thakur M; Simko S; Wan Rachel Tam N; Ferrari A
Pediatr Blood Cancer; 2018 May; 65(5):e26947. PubMed ID: 29350463
[TBL] [Abstract][Full Text] [Related]
20. Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAF
Yilmaz M; Güven Meşe Ş
J Oncol Pharm Pract; 2020 Oct; 26(7):1754-1758. PubMed ID: 32223367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
